Skip to main content
SpringerLink
Log in

Salmeterol/fluticasone cost effective in asthma in Canada

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by GlaxoSmithKline Canada, Inc.

Reference

  • Ismaila AS, et al. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair) in uncontrolled asthma in Canada. Respiratory Medicine : 25 Jun 2014. Available from: URL: 10.1016/j.rmed.2014.06.005

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salmeterol/fluticasone cost effective in asthma in Canada. PharmacoEcon Outcomes News 711, 30 (2014). https://doi.org/10.1007/s40274-014-1539-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1539-y

Search

Navigation